Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
TRVN Stock Summary
Top 10 Correlated ETFs
TRVN
In the News
Go Beyond Bargain Hunting; Buy 5 Stocks With Rising P/E
Tap five stocks with increasing P/E ratios to try out a different approach. These stocks include OpGen (OPGN), The RealReal (REAL), Trevena (TRVN), ChargePoint (CHPT) and Caterpillar (CAT).
5 Hot Penny Stocks To Watch With Big News This Week
Whether you're trading penny stocks or higher-priced company shares, everyone wants to gain an edge. In the stock market today, there are plenty of catalysts to consider.
‘It's ridiculous.' Buy short-term Treasury bills because debt-ceiling deal will come, says bond legend Bill Gross
Friday's bullish session on Wall Street seems to have gone nowhere, save for the Nasdaq Composite COMP wriggling its way out of a bear market.
Trevena to Release First Quarter 2023 Financial Results on May 15, 2023
CHESTERBROOK, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for the first quarter ended March 31, 2023, prior to the market open on Monday, May 15, 2023.
Momentum Trading With Penny Stocks: Quick Guide
Use these tips to make money when momentum trading penny stocks The post Momentum Trading With Penny Stocks: Quick Guide appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Trevena stock soars toward 5-fold gain in very active trading, after pain treatment gets approved in China
Shares of Trevena Inc. TRVN exploded more than five-fold higher — up 420.6% — on very active trading Monday, after the Pennsylvania-based biopharmaceutical company said its China-based partner Jiangsu Nhwa received formal approval from China health regulators for the pain treatment Olinvyk. The stock, which had been halted 21 times for volatility since the open, has seen 75.7 million shares change hands, compared with the full-day average over the past 30 days of about 111,100 shares.
Best Penny Stocks To Buy Now? 4 To Watch Before May CPI Data
Are these the best penny stocks to buy right now? Here's what's moving on Monday.
Why Is Trevena (TRVN) Stock Up 165% Today?
Trevena (NASDAQ: TRVN ) stock is rocketing higher on Monday after Chinese partner Jiangsu Nhwa got approval for one of its treatments. The National Medical Products Administration granted approval to Jiangsu Nhwa for Trevena's OLINVYK.
Trevena to Participate in Three Upcoming Conferences
CHESTERBROOK, Pa., May 03, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that members of Management will participate in three upcoming conferences.
Trevena, Inc. (TRVN) Q4 2022 Earnings Call Transcript
Trevena, Inc. (NASDAQ:TRVN ) Q4 2022 Earnings Conference Call March 30, 2023 8:00 AM ET Company Participants Barry Shin - Chief Financial Officer Carrie Bourdow - President and Chief Executive Officer Patty Drake - Chief Commercial Officer Mark Demitrack - Chief Medical Officer Conference Call Participants Jason Butler - JMP Securities Brandon Folkes - Cantor Fitzgerald Douglas Tsao - H.C. Wainwright Operator Greetings, and welcome to the Trevena Fourth Quarter and Full Year 2022 Earnings Call.
TRVN Financial details
TRVN Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 1.95 | 0.01 | 0.6 | 0.09 | -0.06 | |
Net income per share | -10.46 | -7.65 | -5.75 | -7.84 | -7.59 | |
Operating cash flow per share | -8.62 | -6.45 | -4.19 | -7.69 | -7.28 | |
Free cash flow per share | -8.68 | -6.45 | -4.2 | -7.69 | -7.28 | |
Cash per share | 20.9 | 9.76 | 21.43 | 10.25 | 5.42 | |
Book value per share | 14.11 | 8.2 | 20.39 | 9.9 | 2.21 | |
Tangible book value per share | 14.11 | 8.2 | 20.39 | 9.9 | 2.21 | |
Share holders equity per share | 14.11 | 8.2 | 20.39 | 9.9 | 2.21 | |
Interest debt per share | 6.67 | 3.92 | 1.53 | 1.09 | 2.97 | |
Market cap | 31.63M | 77.12M | 273.12M | 95.19M | 10.11M | |
Enterprise value | 16.13M | 58.28M | 171.52M | 35.37M | -8.44M | |
P/E ratio | -1.03 | -2.75 | -9.3 | -1.86 | -0.19 | |
Price to sales ratio | 5.52 | 2.49K | 88.99 | 167.89 | -24.19 | |
POCF ratio | -1.25 | -3.26 | -12.77 | -1.9 | -0.2 | |
PFCF ratio | -1.24 | -3.26 | -12.75 | -1.9 | -0.2 | |
P/B Ratio | 0.76 | 2.56 | 2.62 | 1.47 | 0.65 | |
PTB ratio | 0.76 | 2.56 | 2.62 | 1.47 | 0.65 | |
EV to sales | 2.81 | 1.88K | 55.89 | 62.38 | 20.2 | |
Enterprise value over EBITDA | -0.58 | -2.51 | -5.82 | -0.68 | 0.15 | |
EV to operating cash flow | -0.64 | -2.46 | -8.02 | -0.7 | 0.16 | |
EV to free cash flow | -0.63 | -2.46 | -8.01 | -0.7 | 0.16 | |
Earnings yield | -0.97 | -0.36 | -0.11 | -0.54 | -5.31 | |
Free cash flow yield | -0.81 | -0.31 | -0.08 | -0.53 | -5.09 | |
Debt to equity | 0.42 | 0.45 | 0.07 | 0.11 | 1.27 | |
Debt to assets | 0.26 | 0.29 | 0.06 | 0.09 | 0.41 | |
Net debt to EBITDA | 0.56 | 0.81 | 3.45 | 1.15 | 0.33 | |
Current ratio | 3.55 | 4.12 | 7.19 | 7.7 | 4.7 | |
Interest coverage | -13.67 | -28.55 | -1.02K | -51.93K | -44.88 | |
Income quality | 0.82 | 0.95 | 0.73 | 0.97 | 0.96 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | -0.01 | -0.04 | -0.01 | 0 | |
Sales general and administrative to revenue | 3.31 | 426.19 | 6.27 | 67.22 | 0 | |
Research and developement to revenue | 2.76 | 428.74 | 4.28 | 23.68 | -43.57 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.01 | 0 | 0 | 0 | 0 | |
Capex to revenue | -0.03 | 0 | -0.01 | -0.03 | 0.07 | |
Capex to depreciation | -0.26 | 0 | -0.06 | -0.04 | -0.07 | |
Stock based compensation to revenue | 0.76 | 104.26 | 1.07 | 7.77 | -8.79 | |
Graham number | 57.64 | 37.58 | 51.37 | 41.78 | 19.41 | |
ROIC | -0.53 | -0.58 | -0.25 | -0.65 | -1.35 | |
Return on tangible assets | -0.46 | -0.6 | -0.23 | -0.64 | -1.1 | |
Graham Net | 12.31 | 5.15 | 18.13 | 8.06 | 0.8 | |
Working capital | 44.6M | 28.38M | 102.48M | 61.54M | 32.28M | |
Tangible asset value | 41.53M | 30.08M | 104.07M | 64.63M | 15.6M | |
Net current asset value | 36.84M | 20.57M | 95.37M | 55.23M | 7.93M | |
Invested capital | 0.42 | 0.45 | 0.07 | 0.11 | 1.27 | |
Average receivables | 0 | 0 | 4.54M | 4.54M | 0.5 | |
Average payables | 1.42M | 1.23M | 1.37M | 3.12M | 3.46M | |
Average inventory | 0 | 0 | 0.5 | 1.18M | 1.63M | |
Days sales outstanding | 0 | 0 | 1.08K | 0 | 0 | |
Days payables outstanding | 0 | 3.54K | 3.4K | 1.74K | 286.87 | |
Days of inventory on hand | 0 | 0 | 0 | 899.87 | 109.57 | |
Receivables turnover | 0 | 0 | 0.34 | 567K | 0 | |
Payables turnover | 0 | 0.1 | 0.11 | 0.21 | 1.27 | |
Inventory turnover | 0 | 0 | 182K | 0.41 | 3.33 | |
ROE | -0.74 | -0.93 | -0.28 | -0.79 | -3.44 | |
Capex per share | -0.06 | 0 | -0.01 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | -0.06 | 0 | 0 | 0.26 | 0.01 | |
Net income per share | -2.17 | -0.78 | -0.62 | -0.69 | -0.57 | |
Operating cash flow per share | -1.55 | -1.11 | -1.13 | -0.63 | -0.64 | |
Free cash flow per share | -1.56 | -1.11 | -1.13 | -0.63 | -0.64 | |
Cash per share | 5.91 | 3.99 | 2.86 | 2.43 | 2.5 | |
Book value per share | 3.2 | 1.63 | 1.06 | 0.84 | 0.25 | |
Tangible book value per share | 3.2 | 1.63 | 1.06 | 0.84 | 0.25 | |
Share holders equity per share | 3.2 | 1.63 | 1.06 | 0.84 | 0.25 | |
Interest debt per share | 3 | 2.12 | 2.09 | 1.83 | 2.54 | |
Market cap | 26.16M | 13.72M | 6.72M | 10.2M | 8.42M | |
Enterprise value | 23.8M | -4.84M | -1.12M | 2.18M | 8.78M | |
P/E ratio | -0.44 | -0.46 | -0.28 | -0.32 | -0.27 | |
Price to sales ratio | -59.71 | 0 | 1.12K | 3.38 | 46.78 | |
POCF ratio | -2.47 | -1.29 | -0.62 | -1.41 | -0.94 | |
PFCF ratio | -2.46 | -1.29 | -0.62 | -1.4 | -0.94 | |
P/B Ratio | 1.2 | 0.88 | 0.66 | 1.04 | 2.37 | |
PTB ratio | 1.2 | 0.88 | 0.66 | 1.04 | 2.37 | |
EV to sales | -54.34 | 0 | -187.36 | 0.72 | 48.79 | |
Enterprise value over EBITDA | -1.54 | 0.52 | 0.11 | -0.35 | -1.06 | |
EV to operating cash flow | -2.24 | 0.45 | 0.1 | -0.3 | -0.98 | |
EV to free cash flow | -2.24 | 0.45 | 0.1 | -0.3 | -0.98 | |
Earnings yield | -0.57 | -0.54 | -0.89 | -0.79 | -0.94 | |
Free cash flow yield | -0.41 | -0.78 | -1.62 | -0.71 | -1.06 | |
Debt to equity | 0.92 | 1.27 | 1.93 | 2.05 | 9.95 | |
Debt to assets | 0.39 | 0.41 | 0.51 | 0.52 | 0.78 | |
Net debt to EBITDA | 0.15 | 1.99 | 0.77 | 1.29 | -0.04 | |
Current ratio | 4.6 | 4.7 | 3.84 | 4.03 | 6.41 | |
Interest coverage | -39.29 | -17.64 | -22.69 | -5.52 | -42.03 | |
Income quality | 0.69 | 1.52 | 1.39 | 0.9 | 1.13 | |
Dividend Yield | 0.55 | 0 | 0 | 0 | 0 | |
Payout ratio | -0.98 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | -12.02 | 0 | 651.5 | 1.32 | 23.67 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0.06 | 0 | 0 | -0.01 | 0 | |
Capex to depreciation | -0.31 | 0.34 | 0 | -0.24 | 0 | |
Stock based compensation to revenue | -1.74 | 0 | 134.33 | 0.23 | 3.83 | |
Graham number | 12.51 | 5.33 | 3.85 | 3.63 | 1.8 | |
ROIC | -0.32 | -0.24 | -0.22 | -0.18 | -0.2 | |
Return on tangible assets | -0.29 | -0.15 | -0.16 | -0.21 | -0.18 | |
Graham Net | 1.7 | 0.59 | -0.03 | -0.05 | -0.43 | |
Working capital | 33.28M | 32.28M | 22.75M | 24.79M | 33.32M | |
Tangible asset value | 21.86M | 15.6M | 10.15M | 9.78M | 3.55M | |
Net current asset value | 13.38M | 7.93M | 2.63M | 3.89M | -2.11M | |
Invested capital | 0.92 | 1.27 | 1.93 | 2.05 | 9.95 | |
Average receivables | 0.5 | 0.5 | 0.5 | 1 | 89.5K | |
Average payables | 2.07M | 1.89M | 2.02M | 2.1M | 2.04M | |
Average inventory | 1.89M | 845.5K | 906K | 903.5K | 900.5K | |
Days sales outstanding | 0 | 0 | 0.02 | 0 | 89.5 | |
Days payables outstanding | 53.82 | 936.32 | 1.18K | 2.58K | 794.57 | |
Days of inventory on hand | 29.84 | 357.63 | 642.05 | 921.48 | 462.86 | |
Receivables turnover | -438K | 0 | 6K | 3.02M | 1.01 | |
Payables turnover | 1.67 | 0.1 | 0.08 | 0.03 | 0.11 | |
Inventory turnover | 3.02 | 0.25 | 0.14 | 0.1 | 0.19 | |
ROE | -0.68 | -0.48 | -0.59 | -0.82 | -2.23 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
TRVN Frequently Asked Questions
What is Trevena, Inc. stock symbol ?
Trevena, Inc. is a US stock , located in Chesterbrook of Pa and trading under the symbol TRVN
What is Trevena, Inc. stock quote today ?
Trevena, Inc. stock price is $0.475 today.
Is Trevena, Inc. stock public?
Yes, Trevena, Inc. is a publicly traded company.